CARDIOMAN is a clinical trial much like the TAZPOWER clinical trial that has just finished. CARDIOMAN refers to CARDIOlipin MANipulation, which highlights the peculiar fat molecule called cardiolipin that is altered in Barth syndrome. In CARDIOMAN, Barth syndrome individuals will be given a pill (or a placebo) of an established medication called bezafibrate that is normally used for treating lipid disorders. This clinical trial is being led by Dr. Colin Steward and is being sponsored/supported by the University Hospitals Bristol National Health Service Foundation Trust of the United Kingdom and by BSF.
The genesis of CARDIOMAN began with researchers who received BSF Research Grants and other support to advance their initial observations. Read publications and watch presentations by Dr. Ren and Dr. Khuchua about how bezafibrate may be therapeutic.